Unknown

Dataset Information

0

Nanoparticle Delivery of Anti-inflammatory LNA Oligonucleotides Prevents Airway Inflammation in a HDM Model of Asthma.


ABSTRACT: To address the problem of poor asthma control due to drug resistance, an antisense oligonucleotide complementary to mmu-miR-145a-5p (antimiR-145) was tested in a house dust mite mouse model of mild/moderate asthma. miR-145 was targeted to reduce inflammation, regulate epithelial-mesenchymal transitions, and promote differentiation of structural cells. In addition, several chemical variations of a nontargeting oligonucleotide were tested to define sequence-dependent effects of the miRNA antagonist. After intravenous administration, oligonucleotides complexed with a pegylated cationic lipid nanoparticle distributed to most cells in the lung parenchyma but were not present in smooth muscle or the mucosal epithelium of the upper airways. Treatment with antimiR-145 and a nontargeting oligonucleotide both reduced eosinophilia, reduced obstructive airway remodeling, reduced mucosal metaplasia, and reduced CD68 immunoreactivity. Poly(A) RNA-seq verified that antimiR-145 increased levels of many miR-145 target transcripts. Genes upregulated in human asthma and the mouse model of asthma were downregulated by oligonucleotide treatments. However, both oligonucleotides significantly upregulated many genes of interferon signaling pathways. These results establish effective lung delivery and efficacy of locked nucleic acid/DNA oligonucleotides administered intravenously, and suggest that some of the beneficial effects of oligonucleotide therapy of lung inflammation may be due to normalization of interferon response pathways.

SUBMITTER: Ramelli SC 

PROVIDER: S-EPMC7013130 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Nanoparticle Delivery of Anti-inflammatory LNA Oligonucleotides Prevents Airway Inflammation in a HDM Model of Asthma.

Ramelli Sabrina C SC   Comer Brian S BS   McLendon Jared M JM   Sandy Lydia L LL   Ferretti Andrew P AP   Barrington Robert R   Sparks Jeff J   Matar Majed M   Fewell Jason J   Gerthoffer William T WT  

Molecular therapy. Nucleic acids 20200114


To address the problem of poor asthma control due to drug resistance, an antisense oligonucleotide complementary to mmu-miR-145a-5p (antimiR-145) was tested in a house dust mite mouse model of mild/moderate asthma. miR-145 was targeted to reduce inflammation, regulate epithelial-mesenchymal transitions, and promote differentiation of structural cells. In addition, several chemical variations of a nontargeting oligonucleotide were tested to define sequence-dependent effects of the miRNA antagonis  ...[more]

Similar Datasets

| S-EPMC5741234 | biostudies-other
| S-EPMC3992277 | biostudies-literature
| S-EPMC3361359 | biostudies-literature
| S-EPMC8684271 | biostudies-literature
| S-EPMC5537454 | biostudies-literature
| S-EPMC5117775 | biostudies-literature
| S-EPMC1763667 | biostudies-literature
| S-EPMC4376484 | biostudies-literature
| S-EPMC5966913 | biostudies-literature
2023-05-15 | GSE220777 | GEO